To estimate the cost of preeclampsia from the national health payer's perspective using secondary data from the SCOPE study (Screening for Pregnancy End Points). SCOPE is an international observational prospective study of healthy nulliparous women with singleton pregnancies. Using data from the Irish cohort recruited between November 2008 and February 2011, all women with preeclampsia and a 10% random sample of women without preeclampsia were selected. Additional health service use data were extracted from the consenting participants' medical records for maternity services which were not included in SCOPE. Unit costs were based on estimates from 3 existing Irish studies. Costs were extrapolated to a national level using a prevalence rate of 5% to 7% among nulliparous pregnancies. Within the cohort of 1774 women, 68 developed preeclampsia (3.8%) and 171 women were randomly selected as controls. Women with preeclampsia used higher levels of maternity services. The average cost of a pregnancy complicated by preeclampsia was €5243 per case compared with €2452 per case for an uncomplicated pregnancy. The national cost of preeclampsia is between €6.5 and €9.1 million per annum based on the 5% to 7% prevalence rate. Postpartum care was the largest contributor to these costs (€4.9-€6.9 million), followed by antepartum care (€0.9-€1.3 million) and peripartum care (€0.6-€0.7 million). Women with preeclampsia generate significantly higher maternity costs than women without preeclampsia. These cost estimates will allow policy-makers to efficiently allocate resources for this pregnancy-specific condition. Moreover, these estimates are useful for future research assessing the cost-effectiveness of preeclampsia screening and treatment.
BackgroundPre-Eclampsia is a multisystem disorder, which can affect both mother and child. It can lead to the development of long term morbidities such as chronic hypertension, increase the risk of hospitalisation and also accounts for a substantial proportion of maternal mortality. The only treatment for pre-eclampsia is delivery which involves increased monitoring during pregnancy. This has substantial health service use implications. However, to date, there has been minimal research examining health service use associated with pre-eclampsia.The aim is to compare health service use among women with and without pre-eclampsia using data from the Screening for Pregnancy Endpoints Study (SCOPE), an international multi-centre prospective study.MethodsCross-sectional analysis of data from the SCOPE study was conducted. SCOPE participants were healthy, nulliparous women with singleton pregnancies recruited between November 2004 and February 2011 in Cork, Ireland (n = 1774). Data were extracted on women with pre-eclampsia (n = 68), and a 10% random sample of women without pre-eclampsia (n = 171). Health service use indicators were divided into antenatal, perinatal and post-natal. Antenatal health service use included number of hospital visits, any hospital admissions, and number of scans. Perinatal indicators included maternal and infant length of hospital stay post-delivery, type of delivery, whether the mother was induced, if an episiotomy or an epidural was performed. Postpartum included admissions of the infant the Neonatal Intensive Care Unit (NICU).ResultsPreliminary results suggest that 44% (n = 30, 95% CI 32–56%]) of women with pre-eclampsia had a caesarean section compared to 25% (n = 43, 95% CI 19–32%]) of women without pre-eclampsia. Furthermore women with pre-eclampsia had longer average length of hospital stay with 24% (n = 16, 95% CI 13–34%]) staying an average of more than five days post-partum compared to 5% (n = 9, 95% CI 2–9%]) of women without pre-eclampsia. 28% (n = 19, 95% CI 17–39%]) of infants born to mothers with pre-eclampsia were admitted to the NICU compared to 9% (n = 16, 95% CI 5–14%]) of infants born to mothers without pre-eclampsia.ConclusionPreliminary results suggest increased obstetric intervention and health service use among women with pre-eclampsia which had resource implications for the health service. The results of this study will be used to estimate the direct health service costs of pre-eclampsia in the absence of current international data.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.